Mozobil Injection, Solution
NDC Package 0024-5862-01
Package Information
Mozobil (plerixafor) injection is plerixafor is used by patients with certain types of cancer (non-Hodgkin's lymphoma-NHL, multiple myeloma-MM) to prepare them for stem cell transplant. This formulation utilizes a injection, solution delivery system. Marketed by Sanofi-aventis U.s. Llc, this product is identified by NDC 0024-5862 and is authorized under FDA application NDA022311.
Identification & Billing
- RxCUI: 828700 - plerixafor 24 MG in 1.2 ML Injection
- RxCUI: 828700 - 1.2 ML plerixafor 20 MG/ML Injection
- RxCUI: 828700 - plerixafor 24 MG per 1.2 ML Injection
- RxCUI: 828703 - Mozobil 24 MG in 1.2 ML Injection
- RxCUI: 828703 - 1.2 ML plerixafor 20 MG/ML Injection [Mozobil]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0024 - Sanofi-aventis U.s. Llc
- 0024-5862 - Mozobil
- 0024-5862-01 - 1 VIAL, SINGLE-USE in 1 CARTON / 1.2 mL in 1 VIAL, SINGLE-USE
- 0024-5862 - Mozobil
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0024-5862-01 identifies a specific commercial package of 1 vial, single-use in 1 carton / 1.2 ml in 1 vial, single-use of Mozobil, a human prescription drug labeled by Sanofi-aventis U.s. Llc. This injection, solution is formulated for subcutaneous use and contains plerixafor as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi-aventis U.s. Llc on September 01, 2013. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Plerixafor is used by patients with certain types of cancer (non-Hodgkin's lymphoma-NHL, multiple myeloma-MM) to prepare them for stem cell transplant. Stem cells, which are found mainly in the bone marrow, turn into red blood cells, white blood cells, and platelets. Plerixafor is used to help stem cells move from the bone marrow to the bloodstream so that the cells can be collected and stored. The stem cells are then infused back into the patient after chemotherapy or radiation.
How is this Sanofi-aventis U.s. Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00024586201. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
